帕博利珠单抗治疗复发/难治性原发性纵隔大B细胞淋巴瘤患者的安全性与耐受性
KEYNOTE-013多队列1b期试验评估帕博利珠单抗治疗复发/难治性原发性纵隔大B细胞淋巴瘤。18例患者入组治疗,17例纳入疗效分析,11例(61%)发生药物相关不良事件,无因不良事件停药。客观缓解率41%(7/17),6例(35%)疾病稳定,中位随访11.3个月,缓解持续时间与总生存均未达到。
要点
- 18例复发/难治性原发纵隔大B细胞淋巴瘤患者接受帕博利珠单抗治疗。
- 11例(61%)发生药物相关不良事件,多为1-2级,无因不良事件停药。
- 客观缓解率41%(7/17),6例(35%)疾病稳定,缓解持续时间未达到。
核心结论
- 在经多线治疗的复发/难治性原发纵隔大B细胞淋巴瘤患者中,帕博利珠单抗的PD-1阻断具有可控的安全性特征和具有前景的抗肿瘤活性。
研究设计与样本
- KEYNOTE-013多队列1b期试验,评估帕博利珠单抗(抗PD-1抗体)治疗复发/难治性原发纵隔大B细胞淋巴瘤的安全性与抗肿瘤活性。
- 数据截止时共18例患者入组并接受治疗(中位年龄30岁;中位既往治疗线数3线),其中17例纳入疗效分析。
- 试验注册于www.clinicaltrials.gov,注册号#NCT01953692。
主要发现
- 11例患者(61%)发生药物相关不良事件,多为1-2级;无患者因不良事件停止治疗。
- 客观缓解率为41%(7/17);另有6例患者(35%)疾病稳定。
- 在可经影像学评估的患者中,16例中有13例(81%)靶病灶缩小。
- 中位随访11.3个月,中位缓解持续时间未达到;2例患者达到最长2年治疗时长并维持缓解。
- 接受治疗患者总体的中位总生存未达到;数据截止时所有缓解者均存活。
关键数值与推荐
- 复发/难治性原发纵隔大B细胞淋巴瘤的预后一般较差(客观缓解率[ORR]0%至25%;2年总生存率15%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort phase 1b trial. At time of data cutoff, 18 patients (median age 30 years; median 3 prior lines of therapy) had been enrolled and treated, of whom 17 were included in the efficacy analyses. Eleven patients (61%) experienced drug-related adverse events (mostly grade 1-2); none discontinued treatment due to adverse events. ORR was 41% (7/17); 6 additional patients (35%) had stable disease. Of patients evaluable by imaging, 13 out of 16 (81%) had decreases in target lesions. With a median follow-up of 11.3 months, median duration of response was not reached. Two patients reached the maximum 2-year treatment duration and remain in remission. Median overall survival was not reached for treated patients overall; all responders were still alive at data cutoff. These results in heavily pretreated rrPMBCL patients demonstrate that PD-1 blockade with pembrolizumab has a manageable safety profile and promising antitumor activity. This trial was registered at www.clinicaltrials.gov as #NCT01953692.
引用
- Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017. PMID: 28490569. doi:10.1182/blood-2016-12-758383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。